ArticleEJNMMI research2022
Clinical utility of
Article in EJNMMI research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A rare case report of pulmonary artery sarcoma diagnosed and managed based on multimodal imaging.European heart journal. Case reports · 2026Article
- Primary Pulmonary Artery Sarcoma: Multimodality Imaging of a Rare Intravascular Tumor Mimicking Pulmonary Embolism.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Developing a deep learning-based imaging diagnostic framework, PVDNet, for differentiating pulmonary artery sarcoma and pulmonary thromboembolism: a multi-center observational study.The Lancet regional health. Western Pacific · 2025Article
- Pulmonary artery intimal sarcoma mimicking pulmonary thromboembolism: A case report and literature review.Oncology letters · 2025Article
- Emerging multimodality imaging techniques for the pulmonary circulation.The European respiratory journal · 2024Review
- Comparison of pulmonary artery sarcoma and pulmonary thromboembolism according to clinical and computed tomography pulmonary angiography and magnetic resonance imaging characteristics: a single-center retrospective study.Quantitative imaging in medicine and surgery · 2024Article
- A primary pulmonary artery sarcoma masquerading pulmonary embolism: a case report and literature review.Thrombosis journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPulmonary artery sarcoma (PAS) is a rare and fatal malignancy. Due to the lack of specific clinical and radiological features, PAS is always misdiagnosed as pulmonary thromboembolism (PTE). This study aimed to investigate
methodsClinical, contrast-enhanced CT, and
resultsThe SUVmax of PAS (median: 8.0, range 3.0-17.2) was significantly higher than PTE (1.8[0.8-3.7]) (P < 0.001), and at a cutoff value of 2.9, the sensitivity and specificity were 100.0% and 93.9%, respectively. Compared with PTE, PAS more frequently occurred in younger population (P = 0.011), involved pulmonary trunk (P < 0.001), and displayed higher enhanced CT (P < 0.001) and ΔCT (enhanced CT compared to non-enhanced CT) (P < 0.001) values. SUVmax of PAS was associated with tumor staging (P = 0.022) and enhanced CT (P = 0.013) and ΔCT (P = 0.005) values. The median OS of PAS patients was 10.5 months, and 12-month and 24-month OS rates were 58.0% and 12.0%, respectively. Only D-dimer level (P = 0.038) and tumor staging (P = 0.019) were associated with OS.
conclusionsMost PAS displayed high glucometabolism, and SUVmax of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.